<?xml version="1.0" encoding="UTF-8"?>
<ref id="R9">
 <label>9</label>
 <mixed-citation publication-type="journal">
  <person-group person-group-type="author">
   <name name-style="western">
    <surname>Zhu</surname>
    <given-names>AX</given-names>
   </name>, 
   <name name-style="western">
    <surname>Finn</surname>
    <given-names>RS</given-names>
   </name>, 
   <name name-style="western">
    <surname>Edeline</surname>
    <given-names>J</given-names>
   </name>, 
   <etal>et al</etal>
  </person-group>
  <article-title>Pembrolizumab in patients with advanced hepatocellular carcinoma previously treated with sorafenib (KEYNOTE-224): a non-randomised, open-label phase 2 trial</article-title>. 
  <source>Lancet Oncol</source>
  <year>2018</year>;
  <volume>19</volume>:
  <fpage>940</fpage>â€“
  <lpage>52</lpage>.
  <pub-id pub-id-type="doi">10.1016/S1470-2045(18)30351-6</pub-id>
  <pub-id pub-id-type="pmid">29875066</pub-id>
 </mixed-citation>
</ref>
